Previous close | 52.50 |
Open | 52.50 |
Bid | 53.00 |
Ask | 56.90 |
Strike | 130.00 |
Expiry date | 2024-08-16 |
Day's range | 52.50 - 52.50 |
Contract range | N/A |
Volume | |
Open interest | 206 |
Novartis (NVS) reports phase III data that confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria.
Krystal Biotech (KRYS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Krystal Biotech (KRYS) soars 36.5% on strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress.